EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer

Mariona Figols iD, Andrea González iD, Maria Fernandez-Saorín, Ana Bautista, Olatz Etxaniz iD, Ester Ruz, Jose Luis Gago iD, Daniela Gómez-Díaz, Juan Carlos Pardo, Marta Galí, Sergi Bernal, Cristina Camps und 5 weitere

Cancers · 24.06.2026 · 18 (13) · 2054

DOI: 10.3390/cancers18132054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 24.06.2026. Verfasst von Mariona Figols und 16 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Althaia Xarxa Assistencial Universitària de Manresa, C/Dr. Joan Soler 1-3, 08243 Manresa, Spain. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Neoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy (RC) is a standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), yet baseline tools to refine prognostic stratification remain limited. We aimed to develop and internally validate a clinicopathological nomogram integrating the neutrophil-to-lymphocyte ratio (NLR) to estimate event-free survival (EFS) in patients with MIBC treated with NAC.

Methods

We retrospectively analyzed 210 patients with cT2–T4aN0–1M0 MIBC treated with cisplatin-based NAC at two Spanish institutions between 2010 and 2021. Candidate predictors included demographic, clinicopathological, and routine laboratory variables. A multivariable Cox model with backward selection based on the Akaike information criterion (AIC) was used to derive the final model, and internal validation was performed using 1000 bootstrap resamples.

Results

Sex, age, prior non–muscle-invasive bladder cancer (NMIBC), and NLR were retained in the final nomogram. The model showed moderate discrimination, with a Harrell’s c-index of 0.60 and an optimism-corrected c-index of 0.58. The nomogram stratified patients into low-, intermediate-, and high-risk groups, with median EFS not reached, 47.5 months, and 18.0 months, respectively. High-risk patients also showed lower pathological complete response (pCR) rates.

Conclusions

This exploratory nomogram integrates an accessible systemic inflammatory marker with baseline clinical variables to identify patients with poorer outcomes despite NAC. External validation in contemporary cohorts is warranted before clinical implementation.

Schlagwörter

Stichwörter der Autor:innen

muscle-invasive bladder cancerneoadjuvant therapynomogramprognosisrisk assessmentsurvival analysis

Autor:innen und Institutionen

  • Medical Oncology Department, Althaia Xarxa Assistencial Universitària de Manresa, C/Dr. Joan Soler 1-3, 08243 Manresa, Spain.
  • PhD Programme in Medicine and Biomedical Sciences, Doctoral School, University of Vic-Central University of Catalonia (UVic-UCC), C/Dr. Junyent 1, 08500 Vic, Spain.
  • Faculty of Medicine, University of Vic-Central University of Catalonia (UVicUCC), Can Baumann Ctra de Roda 70, 08500 Vic, Spain.
  • Medical Oncology Department, Catalan Institute of Oncology, Camí de les Escoles, s/n, 08916 Badalona, Spain.
  • CARE Program, Germans Trias i Pujol Research Institute (IGTP), Camí de les Escoles, s/n, 08916 Badalona, Spain.
  • Badalona Applied Research Group in Oncology (B·ARGO), Catalan Institute of Oncology, Camí de les Escoles, s/n, 08916 Badalona, Spain.

ORCID-Profile: Mariona Figols, Andrea González, Olatz Etxaniz, Jose Luis Gago, Vicenç Ruiz de Porras, Anna Esteve

Zitieren

APA

Figols, M., González, A., Fernandez-Saorín, M., Bautista, A., Etxaniz, O., Ruz, E., Gago, J. L., Gómez-Díaz, D., Pardo, J. C., Galí, M., Bernal, S., Camps, C., Rifa, L., Domenech, M., Ruiz de Porras, V., Esteve, A., & Font, A. (2026). Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer. Cancers, 18(13), 2054. https://doi.org/10.3390/cancers18132054

Vancouver

Figols M, González A, Fernandez-Saorín M, Bautista A, Etxaniz O, Ruz E, et al. Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer. Cancers. 2026;18(13):2054. doi:10.3390/cancers18132054

BibTeX
@article{Figols2026,
  author = {Figols, Mariona and González, Andrea and Fernandez-Saorín, Maria and Bautista, Ana and Etxaniz, Olatz and Ruz, Ester and Gago, Jose Luis and Gómez-Díaz, Daniela and Pardo, Juan Carlos and Galí, Marta and Bernal, Sergi and Camps, Cristina and Rifa, Lorena and Domenech, Montserrat and Ruiz de Porras, Vicenç and Esteve, Anna and Font, Albert},
  title = {Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {13},
  pages = {2054},
  doi = {10.3390/cancers18132054}
}
Kostenlos starten →